Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?
2017; Future Medicine; Volume: 13; Issue: 30 Linguagem: Inglês
10.2217/fon-2017-0336
ISSN1744-8301
AutoresAlessandra Fabi, Diana Giannarelli, Luca Moscetti, Daniele Santini, Alberto Zambelli, Michelino De Laurentiis, Michele Caruso, Daniele Generali, Enrichetta Valle, V. Leonardi, Katia Cannita, Grazia Arpino, Gianfranco Filippelli, G. Ferretti, Marianna Giampaglia, Filippo Montemurro, Cecilia Nisticò, Simona Gasparro, Francesco Cognetti,
Tópico(s)Chronic Lymphocytic Leukemia Research
ResumoAim: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen. Patients & methods: Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73). Results: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progression-free survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14–3.58; p = 0.01). Conclusion: Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting.
Referência(s)